TABLE 2.
Characteristics of HCV RNA–negative patients previously treated with antivirals who achieved a sustained virological response and developed HCC
| Patient | Gender | Diagnosis | Age at HCC, years | Cirrhosis | Therapy type | HCC after therapy, years | Last ferritin (peak) (ng/ml) before HCC | Last LIC (peak) (mg/g dw) before HCC |
|---|---|---|---|---|---|---|---|---|
| 1 | Female | TDT | 50 | Yes | DAA | 4 | 653 (773) | 4.1 (5) |
| 2 | Male | TDT | 46 | Yes | DAA | 4 | 290 (9100) | 5.5 (23.3) |
| 3 | Male | TDT | 40 | Yes | DAA | 1 | 81 (2250) | 1.2 (5.5) |
| 4 | Male | SCD | 43 | Yes | DAA | 2 | 727 (2710) | 11.89 (11.89) |
| 5 | Female | TDT | 55 | No | DAA | 5 | 351 (3998) | 2.4 (6.6) |
| 6 | Female | TDT | 47 | No | IFN + RIBA | 3 | 241 (1850) | 2 (3.89) |
| 7 | Male | TDT | 53 | Yes | DAA | 5 | 543 (NA) | 3.88 (—) |
| 8 | Female | TDT | 51 | Yes | IFN + RIBA | 4 | 929 (1632) | 9.5 (—) |
| 9 | Male | TDT | 39 | — | IFN | 6 | — (—) | — (—) |
| 10 | Male | TDT | 39 | Yes | DAA | 1 | 395 (3890) | 2.9 |
| 11 | Female | SCD | 57 | Yes | DAA | 4 | 272 (—) | — (—) |
| 12 | Male | SCD | 32 | No | NA | >3 | 5686 (7147) | 10.4 (20.5) |
| 13 | Male | TDT | 52 | Yes | DAA | 2 | 854 (2098) | 5.53 (5.53) |
| 14 | Male | TDT | 44 | Yes | IFN + RIBA | 3 | 483 (2384) | 7.44 (18.22) |
| 15 | Male | TDT | 46 | Yes | IFN | 18 | 788 (4851) | 6.96 (6.96) |
| 16 | Male | TDT | 46 | Yes | IFN + RIBA | 3 | 357 (9200) | 5.28 (21.4) |
| 17 | Male | TDT | 43 | No | DAA | 1 | 204 (—) | 1.4 (10.37) |
| 18 | Female | TDT | 37 | Yes | DAA | 2 | 225 (5000) | 2.04 (13.2) |
| 19 | Female | TDT | 51 | No | IFN + RIBA | 8 | 643 (1631) | 2.73 (13.86) |
Abbreviations: DAA, direct antiviral agent; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; LIC, liver iron concentration; NA, not available; RIBA, ribavirin; SCD, sickle cell disease; TDT, transfusion‐dependent β‐thalassemia.